Dextroamphetamine-Amphetamine for ADHD and Narcolepsy

Dextroamphetamine-amphetamine is a prescription stimulant containing a specific blend of amphetamine salts, most widely recognized by the brand name Adderall. It combines two amphetamine isomers in a roughly 3:1 ratio favoring the more potent dextro form, and it is approved for treating attention-deficit/hyperactivity disorder and narcolepsy. The medication has been one of the most commonly prescribed stimulants in the United States for decades, though its story involves more complexity than most patients realize, from how it actually changes brain chemistry to why pharmacies have periodically struggled to keep it in stock.

How It Works in the Brain

Amphetamine’s main job is to increase the amount of certain chemical messengers, primarily dopamine and norepinephrine, floating around in the spaces between nerve cells. It does this through several routes at once. It enters nerve terminals and pushes stored dopamine and norepinephrine out of tiny storage compartments called vesicles into the surrounding cell fluid, then forces that extra neurotransmitter out of the cell entirely through transporter proteins that normally work in the opposite direction. Research on dozens of amphetamine-related compounds has confirmed that this release from vesicles happens through a carrier-mediated exchange mechanism rather than simply disrupting the chemical environment inside the vesicle.

Amphetamine also blocks the reuptake of these neurotransmitters, meaning less gets vacuumed back into the nerve cell after release. The net result is a flood of dopamine and norepinephrine in brain regions responsible for attention, motivation, and executive function. In people with ADHD, where baseline signaling in these pathways tends to be lower than typical, that boost helps bring focus, impulse control, and working memory closer to normal levels. In everyone else, the same flood produces the wakefulness, euphoria, and appetite suppression that make amphetamines both useful and potentially habit-forming.

The 3:1 Ratio and Available Formulations

What makes dextroamphetamine-amphetamine distinct from plain dextroamphetamine is the blend. The product contains a mixture of amphetamine aspartate, amphetamine sulfate, dextroamphetamine saccharate, and dextroamphetamine sulfate. The dextro isomer makes up about three-quarters of the active ingredient, with the levo isomer accounting for the rest. This 3:1 ratio was carried forward when the extended-release version was developed.

The immediate-release tablet is typically taken once or twice daily, with effects lasting roughly four to six hours per dose. The extended-release capsule uses a two-stage bead system: half the pellets dissolve right away, and the other half have a coating that delays their release by about four hours. This design mimics the effect of taking two immediate-release doses spaced apart, providing coverage through a full school or work day on a single morning dose. Pharmacokinetic studies show that the extended-release capsule shifts peak blood levels about three hours later compared to the immediate-release tablet for both amphetamine isomers.

One practical wrinkle involves stomach acid. A study comparing the extended-release formulation taken with and without omeprazole (a common acid-reducing medication) found that over half the participants on the amphetamine salt mixture showed an earlier peak concentration when stomach acid was suppressed, with the median time to peak shifting from five hours to under three hours. Lisdexamfetamine, a different stimulant discussed below, was far less affected by the same acid change.

⁴

Effectiveness for ADHD

The evidence for dextroamphetamine-amphetamine in ADHD is strong across both age groups that have been studied. In adults, one of the earlier controlled trials found that treatment at an average dose of around 54 mg per day (split into two doses) led to roughly a 42% decrease in ADHD symptom ratings, with 70% of participants meeting the threshold for meaningful improvement compared to just 7% on placebo.

⁵

A Cochrane systematic review pooling data from multiple trials confirmed that both mixed amphetamine salts and lisdexamfetamine reduced ADHD symptom severity in adults compared to placebo, though the overall quality of evidence was rated as low, mostly because of high dropout rates and short study durations rather than because the drugs did not appear to work.

⁶

How It Compares to Methylphenidate

Methylphenidate (the active ingredient in Ritalin and Concerta) is the other major stimulant class prescribed for ADHD. The two drug families work differently at the molecular level: methylphenidate primarily blocks the reuptake of dopamine and norepinephrine, while amphetamine also actively forces those neurotransmitters out of nerve cells. You might expect that difference to translate into clearly distinct clinical profiles, but the real-world picture is muddier. A large review concluded that there is no conclusive clinical evidence supporting a choice of one drug class over the other based on their mechanisms of action.

⁷

That said, head-to-head comparisons in children found that the doses of dextroamphetamine-amphetamine tested produced greater improvement than the doses of methylphenidate tested on many measures, particularly later in the day when methylphenidate’s effects were wearing off. The researchers attributed this partly to the doses being functionally more potent rather than to an inherent superiority of one drug, noting that a lower dose of the amphetamine product produced effects comparable to a higher dose of methylphenidate.

⁸

In practice, clinicians often try one class first and switch to the other if the response is inadequate or side effects are intolerable. Roughly a third of patients who do not respond well to one stimulant class do better on the other, which is why guidelines typically recommend trying both before moving to non-stimulant options.

Lisdexamfetamine as a Prodrug Alternative

Lisdexamfetamine (brand name Vyvanse) is chemically dextroamphetamine bonded to the amino acid lysine. Your body has to cleave that bond, which happens in the bloodstream, before the active drug becomes available. This prodrug design produces a smoother rise and fall in blood levels, with a lower peak concentration and less variability between doses compared to an equivalent amount of immediate-release dextroamphetamine.

⁹

The practical upside is twofold. First, the gradual onset means the subjective “rush” is blunted, which reduces how much users like the drug recreationally. Drug-liking scores for lisdexamfetamine are lower than for an equivalent dose of immediate-release dextroamphetamine. Second, because the conversion happens in the blood rather than in the stomach, changes in stomach acid or crushing the capsule do not meaningfully speed up absorption the way they can with the extended-release amphetamine salt mixture. For patients who also take acid-reducing medications like proton-pump inhibitors, this stability can matter clinically.

¹⁰

Use in Narcolepsy

Dextroamphetamine-amphetamine has been used for decades to manage excessive daytime sleepiness in narcolepsy. It remains on the books as an approved indication, but the evidence base is surprisingly thin compared to its ADHD data. Most of the knowledge about how to dose and monitor amphetamines for narcolepsy comes from clinical experience rather than large randomized trials, and researchers have called for a better understanding of optimal dosing strategies and long-term outcomes in this population.

¹¹

Newer agents like sodium oxybate, modafinil, and solriamfetol have largely taken over as first-line narcolepsy treatments because they have more robust trial data and, in some cases, fewer regulatory hurdles around prescribing. Still, amphetamines remain a useful fallback when those options fail or are not tolerated.

Does It Actually Make Healthy People Smarter?

The short answer is: barely, if at all, and mostly only if your baseline performance was low to begin with. A study giving mixed amphetamine salts to healthy young adults found no overall enhancement across a battery of cognitive tests. The one exception was that participants with lower baseline abilities showed modest improvements in word recall and certain pattern-recognition tasks. The more striking finding was about perception: despite the lack of measurable cognitive benefit, participants consistently believed the drug was enhancing their performance more than placebo.

¹²

A systematic review of stimulant use in young people without ADHD reached a similar conclusion. Amphetamine improved memory consolidation and recall modestly, but cognitive enhancement across broader domains was not supported. The drug appeared to help people with low baseline scores on specific tasks while doing little for those already performing well.

¹³

This gap between perceived and actual benefit likely fuels the demand for stimulants on college campuses. If a drug makes you feel sharper, more focused, and more productive, you will keep using it even if your test scores do not actually improve.

Cardiovascular and Psychiatric Safety

All stimulants raise heart rate and blood pressure modestly. The clinical question has always been whether that translates into more heart attacks and strokes. A systematic review of population-based studies found a split by age group: six out of seven studies in children and adolescents showed no association between stimulant use and serious cardiovascular events, while two out of three studies in adults did find an association.

¹⁴

This age discrepancy makes intuitive sense. Children generally have healthy arteries with plenty of reserve, so a small bump in blood pressure rarely tips them into a cardiovascular event. Adults, especially those with preexisting hypertension or arterial disease, sit closer to the threshold where those same changes could matter. Current guidelines recommend checking blood pressure and heart rate before and during treatment, and avoiding stimulants in people with structural heart disease or uncontrolled hypertension.

On the psychiatric side, stimulants can occasionally trigger or worsen psychosis, mania, or severe anxiety, particularly at high doses. Case reports describe persistent psychotic symptoms in people who exceeded their prescribed dose of dextroamphetamine-amphetamine, sometimes requiring antipsychotic treatment.

¹⁵

Growth in Children

Parents of children on stimulants often worry about height. The concern is legitimate. Data from the MTA study, one of the largest ADHD treatment trials, found that children who began stimulant medication showed a growth deficit of about 2 cm in height and 2.7 kg in weight compared to unmedicated peers over three years. The gap appeared to plateau by the 36-month mark rather than widening indefinitely.

¹⁶

The longer-term picture is less clear. Research on whether children eventually catch up to their expected adult height after stopping medication is limited, but the general consensus from available data is that the rate of height loss is relatively small and likely reversible once treatment ends.

¹⁷

Pregnancy Considerations

The safety of amphetamines during pregnancy is an area where the evidence sends somewhat mixed signals. A large international cohort study found that first-trimester amphetamine exposure was not associated with an increased risk of birth defects overall or cardiac malformations specifically, with adjusted risk ratios close to 1.0 for both outcomes.

¹⁸

However, a separate case-control study from the National Birth Defects Prevention Study found that early pregnancy use of ADHD medications was more commonly reported by mothers of infants with certain abdominal wall and limb defects, though the absolute numbers were small and the confidence intervals wide.

¹⁹

Given the conflicting data, most clinicians recommend discontinuing stimulants during pregnancy when possible, but acknowledge that severe untreated ADHD carries its own risks, including impaired self-care and higher accident rates. The decision is individualized, and current guidelines do not classify amphetamines as outright contraindicated in pregnancy.

Tolerance, Dependence, and Withdrawal

Tolerance to stimulants is real but tends to develop unevenly. Many patients find that the appetite-suppressing and euphoric effects fade relatively quickly, while the attention-improving effects remain more stable over time. The neuroscience behind this unevenness involves complex adaptations in dopamine signaling. Chronic amphetamine use triggers changes in the sensitivity of dopamine receptors and the intracellular signaling machinery they connect to, particularly in reward-related brain regions.

²⁰

Dopamine systems appear to be central to both the development of tolerance and the phenomenon of sensitization, where certain behavioral responses to the drug actually intensify with repeated use rather than diminishing. Animal studies have confirmed that dopamine pathways are a critical link in both processes, even though the biochemical details do not always align neatly with the behavioral changes observed.

²¹

Stopping amphetamines after prolonged use produces a withdrawal period often described as a “crash.” In animal models, the first two days after discontinuation show the most pronounced drop in spontaneous activity, with depressive-like behavior still evident at one week but largely resolved by four weeks. Researchers have drawn parallels between this pattern and the fatigue, low mood, and sleep disruption that humans experience during amphetamine withdrawal.

²²

For patients taking therapeutic doses under medical supervision, physical dependence is usually mild. Withdrawal symptoms after stopping prescribed doses are uncomfortable but not medically dangerous, and tapering over a few days is generally sufficient. The picture is different for people using high doses recreationally, where the withdrawal can be more intense and cravings more persistent, driven by the deep embedding of drug-related cues into the brain’s reward circuitry.

²³

Misuse and Diversion

Stimulant misuse is concentrated among young adults. A systematic review found that nonprescribed stimulant use in the past year ranged from 5% to 9% among school-age children and 5% to 35% among college-age individuals. The most common reasons people gave for using someone else’s stimulant were to concentrate, improve alertness, experiment, or get high. The risk was higher among people using immediate-release formulations compared to extended-release versions, presumably because the faster onset creates a more noticeable subjective effect.

²⁴

This is one area where the choice of formulation has real public health implications. Extended-release capsules and prodrugs like lisdexamfetamine are harder to abuse by design: they resist dose-dumping if crushed, and the slower absorption curve reduces the rewarding peak that drives recreational use.

Drug Interactions and Metabolism

Amphetamine is sometimes described as having minimal drug interactions, but that framing oversimplifies things. The drug’s metabolism is unusual in that it does not rely heavily on the liver enzymes that process most other medications. In vitro studies found that amphetamine and dextroamphetamine did not undergo substantial breakdown in human liver preparations, and the role of the CYP2D6 enzyme appeared very minimal.

²⁵

Instead, a significant fraction of amphetamine is excreted unchanged by the kidneys, which means urine pH has an outsized influence on how long the drug stays in your system. Acidic urine speeds elimination; alkaline urine slows it. Anything that shifts urine pH, from antacids to large dietary changes, can alter how much drug is in your bloodstream at any given time. The more relevant interactions tend to be pharmacodynamic rather than pharmacokinetic: combining amphetamine with MAO inhibitors can cause a dangerous spike in blood pressure, and mixing it with serotonergic drugs raises serotonin syndrome risk.

²⁶

The Neurotoxicity Question

Whether therapeutic doses of amphetamine cause lasting brain damage is one of the more uncomfortable open questions in psychopharmacology. High doses, on the scale used by people with addiction, clearly damage dopamine-producing nerve endings. But a primate study found that even doses designed to mimic clinical ADHD treatment damaged dopaminergic nerve endings in the striatum, and the blood levels associated with that damage were in the range seen in young patients on prescribed amphetamine.

²⁷

Other animal research using similar therapeutic-level dosing tells a different story, showing evidence of dendritic growth rather than damage, suggesting the drug might have a nourishing rather than toxic effect on certain brain structures at low doses.

²⁸

These findings are genuinely contradictory, and the field has not resolved them. The primate study is alarming but involved a small number of animals and a specific dosing schedule that may not perfectly map to how humans take the drug over years. The rat studies showing trophic effects used a different species and dosing paradigm. Neither result can be easily dismissed, and neither has been definitively replicated in long-term human imaging studies. For now, the clinical consensus is that the known benefits of treatment in people with diagnosed ADHD outweigh the theoretical risk, but the question deserves more attention than it gets.

The Supply Shortage

Starting in late 2022, dextroamphetamine-amphetamine became difficult or impossible to find at many pharmacies across the United States. The shortage was widely attributed to DEA production quotas, but an analysis published in JAMA Health Forum pointed to a different culprit. The data suggested that manufacturers collectively had enough quota to raise production, but an unprecedented drop in US imports of the active pharmaceutical ingredient coincided with the shortage. The simultaneous but modest decline in imports of a key precursor chemical in 2022, rather than federal quotas, likely made it impossible for some manufacturers to meet demand.

²⁹

Demand had also been climbing following the COVID-19 pandemic, when telehealth made it easier to obtain ADHD diagnoses and prescriptions. That combination of rising demand and disrupted supply created a squeeze that affected millions of patients, many of whom had to switch medications, ration doses, or go without treatment entirely. The shortage has highlighted how vulnerable the supply chain for a Schedule II controlled substance can be when raw material imports falter, regardless of what regulators allow manufacturers to produce.

Medication Adherence When Teens Become Adults

One of the less-discussed challenges with long-term ADHD treatment is what happens during the transition from adolescence to adulthood. A study tracking medication adherence found that it dropped steeply from about 37% at age 17 to roughly 19% by age 19.

³⁰

The reasons are both structural and psychological. Young adults often lose access to the pediatrician or child psychiatrist who managed their care, and finding an adult provider comfortable prescribing controlled substances can be difficult. Insurance transitions, moving away for college, and the simple desire to see whether they can manage without medication all contribute. Claims database analyses show that patients with co-occurring psychiatric conditions such as anxiety or depression were more likely to remain on certain stimulant formulations during this period, possibly because their symptoms were severe enough to motivate continued care.

³¹

1
The Journal of Pharmacology and Experimental Therapeutics. Interaction of Amphetamines and Related Compounds at the Vesicular Monoamine Transporter ↩︎
2
PubMed. Safety, efficacy and extended duration of action of mixed amphetamine salts extended-release capsules for the treatment of ADHD ↩︎
3
PubMed. Pharmacokinetics of SLI381 (ADDERALL XR), an extended-release formulation of Adderall ↩︎
4
PubMed. Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults ↩︎
5
Archives of General Psychiatry. Efficacy of a Mixed Amphetamine Salts Compound in Adults With Attention-Deficit/Hyperactivity Disorder ↩︎
6
PubMed Central. Amphetamines for Attention Deficit Hyperactivity Disorder (ADHD) in adults ↩︎
7
PubMed Central. The Pharmacology of Amphetamine and Methylphenidate: Relevance to the Neurobiology of Attention-Deficit/Hyperactivity Disorder and Other Psychiatric Comorbidities ↩︎
8
PubMed. A comparison of ritalin and adderall: efficacy and time-course in children with attention-deficit/hyperactivity disorder ↩︎
9
PubMed Central. Lisdexamfetamine Dimesylate: Prodrug Delivery, Amphetamine Exposure and Duration of Efficacy ↩︎
10
PubMed Central. Lisdexamfetamine Dimesylate: Prodrug Delivery, Amphetamine Exposure and Duration of Efficacy ↩︎
11
PubMed Central. The Treatment of Narcolepsy With Amphetamine-Based Stimulant Medications: A Call for Better Understanding ↩︎
12
PubMed. Objective and subjective cognitive enhancing effects of mixed amphetamine salts in healthy people ↩︎
13
PubMed Central. Efficacy of stimulants for cognitive enhancement in non-attention deficit hyperactivity disorder youth: a systematic review ↩︎
14
PubMed Central. Do prescription stimulants increase the risk of adverse cardiovascular events?: A systematic review ↩︎
15
PubMed Central. Adderall-Induced Persistent Psychotic Disorder Managed With Long-Acting Injectable Haloperidol Decanoate ↩︎
16
PubMed. Effects of stimulant medication on growth rates across 3 years in the MTA follow-up ↩︎
17
PubMed Central. ADHD stimulants and their effect on height in children ↩︎
18
JAMA Psychiatry. Association Between Methylphenidate and Amphetamine Use in Pregnancy and Risk of Congenital Malformations: A Cohort Study From the International Pregnancy Safety Study Consortium ↩︎
19
PubMed Central. ADHD Medication Use During Pregnancy and Risk for Selected Birth Defects: National Birth Defects Prevention Study, 1998–2011 ↩︎
20
Neuron. Molecular and Cellular Mechanisms of Psychostimulant Action ↩︎
21
Pharmacology Biochemistry and Behavior. Chronic amphetamine: Is dopamine a link in or a mediator of the development of tolerance and reverse tolerance? ↩︎
22
PubMed Central. Time course of transient behavioral depression and persistent behavioral sensitization in relation to regional brain monoamine concentrations during amphetamine withdrawal in rats ↩︎
23
PubMed Central. Neurobiologic processes in drug reward and addiction ↩︎
24
PubMed. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature ↩︎
25
PubMed. Characterisation of seven medications approved for attention-deficit/hyperactivity disorder using in vitro models of hepatic metabolism ↩︎
26
PubMed. Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder ↩︎
27
The Journal of Pharmacology and Experimental Therapeutics. Amphetamine Treatment Similar to That Used in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder Damages Dopaminergic Nerve Endings in the Striatum of Adult Nonhuman Primates ↩︎
28
PubMed. Update on amphetamine neurotoxicity and its relevance to the treatment of ADHD ↩︎
29
JAMA Health Forum. Manufacturing Supply Chains and Imports in the ADHD Drug Shortage ↩︎
30
PubMed. Attention-Deficit/Hyperactivity Disorder Medication Adherence in the Transition to Adulthood: Associated Adverse Outcomes for Females and Other Disparities ↩︎
31
PubMed Central. Disruption of Pharmacotherapy During the Transition from Adolescence to Early Adulthood in Patients with Attention-Deficit/Hyperactivity Disorder: A Claims Database Analysis Across the USA ↩︎